BioSpace News Archive

Freeline Therapeutics Holdings plc announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value £0.00001 per share, from the current ADS Ratio of one ADS to one ordinary share to a new ADS Ratio of one ADS to fifteen ordinary shares.

Enzolytics, Inc. announced that the Company’s representative traveled to Africa to arrange for the delivery of its ITV-1 immunotherapy treatments to African hospitals and to finalize the information to be included on product labels as required by the African regulatory agencies.

Kodiak Sciences Inc. announced today that multiple scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, being held from April 23 – 27 in New Orleans, United States.

EDAP TMS SA (Nasdaq: EDAP) (“the Company”) today announced that the Company will be showcasing its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held April 28th through May 1st in Chicago, IL.

Solid Biosciences Inc. today announced that Solid management will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET.

CXL Ophthalmics’ CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium.

Guardant Health, Inc. is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC).

Clearmind Medicine Inc. announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc’s Palmitoylethanolamide (PEA) for the treatment of depression.

SciSparc Ltd. announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, and Joseph Frattaroli, Chief Financial Officer of Inhibikase, will deliver a presentation at the 2023 Planet MicroCap Showcase being held on April 25-27, 2023 in Las Vegas, Nevada.